Extravasation detector
Abstract
Ultrasound Doppler probe 2 is placed above the vein downstream of a contrast medium infusion site and measures the flow velocity in the vein. Processor 4 converts the output from the probe 2 into a form that may be displayed as an image on display unit 5. It also determines whether the velocity corresponds to a flow of contrast medium along the vein. If the cannula 13 is properly sited and the contrast medium as desired along the vein, this will lead to an increased flow velocity in the vein. This is detected by ultrasound probe 2 and the processor 4 will determine that no extravasation has occurred. However, where extravasation of contrast medium occurs a low or zero output from probe 2 will result and processor 4 determines that extravasation has occurred, and it immediately sends a "stop" signal, e.g. an alarm, to pump controller 11 which stops pump 10.

Term
Term ended
Expired 4 December 2023, 2.8 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
17 claims: 10 independent, 7 dependent
- 1A method of detecting extravasation during the intended infusion of a substance into a blood vessel characterized by the step of detecting a change in the flow velocity within the blood vessel downstream of the point of infusion.
- 5A method as claimed in any preceding claim, wherein flow velocity changes are continuously or repeatedly monitored during the procedure.
- 6A method as claimed in any preceding claim, further comprising the provision of a notification that extravasation has occurred.
- 7A method as claimed in any preceding claim, further comprising the automatic shutdown of the infusion in response to the detection of extravasation.
- 8A method as claimed in any preceding claim, wherein extravasation is indicated by detecting a lack of a flow velocity increase after the intended infusion has commenced.
- 9An apparatus for detecting extravasation during the intended infusion of a substance into a blood vessel comprising a detector (2), the apparatus being arranged to provide an output signal when extravasation occurs characterized in that the detector (2) is a detector for detecting a change in the flow velocity within the blood vessel downstream of the point of infusion.
Independent claims10
41 paragraphs, as filed
0001The present invention relates to an apparatus and method for detecting extravasation.
0002There are numerous medical procedures in which it is necessary to infuse a substance into a blood vessel. Typically a cannula is inserted into a vein and the substance is fed to this via a flexible tube. The substance may be blood, saline, a drug, a contrast medium, etc. In many cases it is desirable that the infusion occurs slowly and so the substance is simply gravity fed. However, there are circumstances in which it is necessary to force the substance into the blood vessel.
0003One example is the infusion of a contrast medium used in conjunction with an imaging system such as angiography, computed tomography (CT), ultrasound or MRI. In many applications of these procedures it is necessary to infuse a contrast medium into the part of the body that is to be imaged. The medium must often be infused at a comparatively high rate for effective results to be achieved. As a consequence, in recent years, a number of injector-actuated syringes and power injectors for pressurized injection of contrast medium have been developed.
0004However, whilst such devices are valuable and effective, they do create a risk of extravasation. Extravasation is the accidental infusion of fluid such as contrast media into tissue surrounding a blood vessel, rather than into the blood vessel itself. The causes for extravasation vary. Fragile vasculature or valve disease may cause physiological limitations to the ability of the blood vessel to tolerate the high rate of fluid administration used in some procedures. In computed tomography, for example, contrast injection flow rates can be in the range of 0.1 to 10 ml/s. and so a failure of the vessel may occur. Alternatively, operator error may lead to inappropriate needle placement and patient movement may cause the infusing needle to be pulled from the intended vessel or cause the needle to be pushed through the wall of the vessel.
0005Extravasation of contrast media during intravenous injection is a potential serious complication that might necessitate surgical drainage of the affected region. Even though the incidence rate is low, it is considered to be a major concern and is associated with local pain and possibly necrosis of the tissue. If it' occurs during an imaging procedure it is often necessary for the examination to be aborted and repeated at a later stage. It is therefore important to be able to detect extravasation quickly and reliably so that infusion may then be stopped. Other substances may have more serious effects. Chemotherapy drugs can be toxic to tissue if not diluted by blood flow.
0006Several extravasation detection techniques are known in the art. Two simple and very useful techniques for detecting extravasation are palpation of the patient in the vicinity of the injection site and simple visual observation of the vicinity of the injection site by a trained health care provider.
0007In the palpation technique, the health care provider manually senses swelling of tissue near the injection resulting from extravasation. By visual observation, it is also sometimes possible to observe directly any swelling of the skin in the vicinity of an injection site resulting from extravasation.
0008There have been a number of attempts to improve the detection of extravasation. For example, mercury strain gauge plethysmographs measure the volume change resulting from venous blood flow in a cross sectional area of a limb of a patient in order to detect a change in volume of a limb or digit as a result of extravasation.
0009Photo-plethysmographs measure the optical scattering properties of capillary blood to detect the presence of extravasated fluids in tissue. <patcit id="pcit0001" dnum="WO9915074A"><text>WO 99/15074</text></patcit> provides a sensor pad having a surface that is placed against a patient. A light source is also provided and a detector on the pad optically detects extravasation by detecting light that is reflected, scattered, etc.
0010<patcit id="pcit0002" dnum="US4647281A"><text>U.S. Patent No. 4,647,281</text></patcit> discloses subcutaneous temperature sensing of extravasation using a microwave radiometer. The temperature of the subcutaneous tissue where the fluid is injected is compared to that of the injected fluid.
0011It is also known to detect extravasation by measuring changes in the electrical impedance. Injection fluid in the tissue of the patient also changes the electrical impedance properties of the tissue. Thus, an impedance change of a certain level in the vicinity of the injection site is interpreted as being due to extravasation. <patcit id="pcit0003" dnum="WO9926686A"><text>WO 99/26686</text></patcit> discloses an electrode patch for attachment to the skin of a patient. It has elongate pick-up electrodes and energizing electrodes. The patch is used to monitor tissue impedance during the procedure and this is compared to a baseline level.
0012A disadvantage of such devices is that it can be difficult to maintain good electrical contact with the skin of the patient. Also, the location of the patch makes it more difficult to carry out palpation or visual inspection. A similar problem arises with the other prior art detectors. In order to address this problem, United States Patent No. <patcit id="pcit0004" dnum="US6408204B"><text>6,408,204</text></patcit> proposes an apparatus that may be positioned so as not to interfere with palpation or visual inspection. An energy source and a receiver are positioned between a first layer of high dielectric material and a second layer of low dielectric material. If extravasation occurs, as noted above, there is a change in the bulk electrical properties of the tissue. The receiver measures a signal resulting from changes in the energy supplied to the tissue by the energy source.
0013<patcit id="pcit0005" dnum="US20020173725A"><text>US 2002/0173725</text></patcit> discloses an adhesive Doppler pad to detect a pulse signal of a patient. Acoustic waves are applied to an artery and the waves reflected from red blood cells are received and the associated Doppler shift is calculated to thereby determine a patient's pulse.
0014<patcit id="pcit0006" dnum="US6425878B"><text>US 6425878</text></patcit> discloses a method and device for detecting extravasation which employs a non-invasive sensor system on the skin to identify changes in subcutaneous interstitial fluid pressure and skin temperature.
0015According to the present invention there is provided a method of detecting extravasation during the intended infusion of a substance into a blood vessel characterized by the step of detecting a change in the flow velocity within the blood vessel downstream of the point of infusion.
0016Thus, unlike the prior art techniques the present invention is not based on volume changes of tissue induced by extravasation, but on direct monitoring of the increased flow velocity within the blood vessel induced by the infusion- The lack of a velocity increase indicates that extravasation has occurred. Since the increase in flow velocity should occur almost immediately infusion commences, this method gives the operator an early warning if a problem occurs.
0017It can be difficult to precisely locate the blood vessel downstream of the point of infusion. Therefore in a preferred embodiment of the invention, an array of detector elements is arranged substantially transverse to the direction of flow of the blood vessel so that at least one element of the array will be located over the vessel. The signal from each detector element varies depending on whether the detector element is located over the blood vessel or over ordinary tissue. This has the advantage that the accuracy with which the detector must be placed is reduced. At least one element of the array will be located over the vessel, and so it is not necessary to precisely locate the blood vessel at the point of measurement prior to commencing the measurement. Instead, a change in flow velocity will be detected by whichever element or elements of the array are located over the blood vessel. The change in flow velocity could be detected by measuring the flow velocity at a single point downstream of the point of infusion. In one preferred embodiment however, the flow velocity within the blood vessel is measured at a plurality of points spaced apart along the extent of the vessel and positioned downstream of the point of infusion. This has the advantage of enabling a user to determine the approximate position within the vessel at which extravasation has occurred.
0018Although the method of the invention is applicable to any infusion of a substance that causes a detectable increase in blood flow velocity, it is of particular use where the infusion is at a high rate where the greatest risk of extravasation occurs. The rates of infusion may be over 5ml/s and sometimes over 10ml/s. Thus, the invention is of particular application to venous infusions such as contrast agents. The invention may therefore be incorporated as part of a process of generating a medical image.
0019The invention could just be applied when the infusion is commenced, or when the rate of infusion is increased, these being times when a problem is most likely to occur. However, as noted above, extravasation may be caused by patient movement and so preferably blood flow velocity changes are continuously or repeatedly monitored during the procedure.
0020In a simple form of the invention, a change in velocity may be noted by an operator who can then stop the infusion. However, it is preferable that the method further comprises the provision of a notification that extravasation has occurred and most preferably there may be automatic shutdown of the infusion in response to the detection of extravasation.
0021The invention also extends to an apparatus for detecting extravasation during the intended infusion of a substance into a blood vessel comprising a detector for detecting a change in the flow velocity within the blood vessel downstream of the point of infusion, the apparatus being arranged to provide an output signal when extravasation occurs.
0022The output signal may be a notification such as an alarm. More preferably it comprises a control signal to control the infusion. The output signal need not be "high" to indicate extravasation. Indeed, it may be preferable to use a fail-safe system in which a "high" output indicates an increased velocity and therefore that extravasation has not occurred. Thus, if the "high" signal is lost, either due to extravasation or equipment failure, the infusion can be stopped.
0023Any suitable method of detecting flow velocity may be applied, but it is believed that the most effective technique is ultrasound Doppler. Thus, the detector is preferably an ultrasound Doppler probe which may consist of a single transducer element and more preferably consists of an array of individual transducer elements adapted to be arranged substantially transverse to the direction of flow of the blood vessel so that the position of the blood vessel can be detected and/or the change in flow velocity in the blood vessel can be detected without first knowing the precise location of the blood vessel. In another embodiment of the invention, a plurality of individual transducer elements (or arrays of transducer elements) are spaced apart along the direction of flow of the blood vessel to form an array (or a two dimensional array) of transducer elements which can track the direction of a blood vessel in use. The probe may be located against the skin of a patient proximate to a vein into which the infusion is being made and downstream of the infusion site. The probe is preferably fixed to the patient's skin using an adhesive. In accordance with standard practice, a coupling medium (ultrasound gel) should preferably be applied to the patient's skin under the transducer elements.
0024The probe may be connected to a display unit in the conventional manner in which case increases in flow velocity will be visible conventionally as bright patches on the display. These may be detected using conventional techniques, for example by comparing pixel brightness in a preselected region on the display. Alternatively, the display can be dispensed with and a direct indication of velocity produced. Normally the velocity of the infusion will be significantly higher than any other velocity of flow in the region concerned and so precise measurement is not required.
0025An analogue signal voltage which is generally proportional to the detected flow velocity may be provided as the output from the detector. This could be used to drive a simply calibrated meter. Additionally or alternatively the voltage may be compared to a threshold voltage such that when this is exceeded an indication is provided that extravasation has (or has not) occurred.
0026In many applications it may be preferable to use a digital system. If the output from the detector is not in digital form then it may be converted using a conventional analogue-digital converter. The output may then be fed to a processor such as a personal computer or a custom processor incorporated into the apparatus.
0027Regardless of the system used, an output control signal may then be provided to control the infusion pump. In a simple form this may operate a relay to cut the power to the pump, or if the pump is computer controlled it may be a digital control signal. Alternatively, a valve arrangement may be used to prevent flow to the vein.
0028It will be appreciated that the invention extends to a system for giving an infusion comprising an infusion pump arranged to infuse a substance into a blood vessel and an extravasation detector according to the apparatus defined above wherein the detector apparatus is arranged to control the infusion pump. The invention also extends to a method of giving such an infusion comprising the use of such apparatus.
0029Certain embodiments of the invention will now be described, by way of example only, and with reference to the accompanying drawings in which:- <ul id="ul0001" list-style="none" compact="compact"><li><figref idref="f0001">Figure 1</figref> is a schematic view of a first embodiment of the invention;</li><li><figref idref="f0001">Figure 2</figref> is a schematic view of a modified version of the <figref idref="f0001">Figure 1</figref> embodiment;</li><li><figref idref="f0002">Figure 3</figref> is a schematic view of an alternative embodiment of the invention;</li><li><figref idref="f0003">Figure 4</figref> is a diagram illustrating the use of the embodiment of <figref idref="f0001">Figure 1</figref> where no extravasation has occurred; and</li><li><figref idref="f0003">Figure 5</figref> is a diagram illustrating the use of the embodiment of <figref idref="f0001">Figure 1</figref> where extravasation has occurred.</li></ul>
0030In <figref idref="f0001">Figure 1</figref> a patient's arm is illustrated at 1. A contrast medium is being infused into the patient from a pump 10. The pump is controlled by an electronic pump controller 11, which varies the pump speed as required and starts and stops it.
0031The contrast medium flows via flexible tube 12 to cannula arrangement 13, which comprises a connector for connection to the flexible tube, and a fine bore tube 14 which has been inserted into a vein in the known manner.
0032Ultrasound Doppler probe 2 is placed above the same vein and a convenient distance downstream so as to be clear of the infusion site. The Doppler probe consists of a single transducer element 2 which in use is placed at an angle to the vein to create and detect a Doppler shift from the flow. The probe 2 is connected via a flexible lead 3 to a processor unit 4. This converts the output from the probe 2 into a form that may be displayed as an image on display unit 5 in the conventional manner. In addition it provides a digital signal proportional to the flow velocity detected by the probe 2. This value is then also displayed on display 5. In addition, the unit 4 determines whether the velocity corresponds to a flow of contrast medium along the vein.
0033When the infusion is to commence, the operator sets the desired infusion rate by inputting it into the pump controller 11 and then inputs a start signal into unit 4 by pressing a key (not shown). This in turn transmits a start signal to the pump controller 11 which energises the pump and causes it to run at the desired speed.
0034The processor unit 4 then checks the flow velocity as described above. If it is not satisfactory within a pre-determined short period of time the infusion will be stopped.
0035As may be seen from <figref idref="f0003">Figure 4</figref>, if the cannula is properly sited and the contrast medium flows as desired along the vein, this will lead to an increased flow velocity in the vein. This is detected by ultrasound probe 2 and, as described above, the processor unit 4 will therefore determine that no extravasation has occurred. It will therefore continue to send a "pump" signal to pump controller 11.
0036<figref idref="f0003">Figure 5</figref> shows the situation that might occur when there is extravasation of contrast medium and consequently no flow in the vein. This results in a low or zero velocity output from the probe 2 from which the processor unit 4 determines that extravasation has occurred. It therefore immediately sends a "stop" signal to pump controller 11 which stops pump 10. In this way, the infusion may be stopped almost as soon as the problem occurs with the result that only a small amount of contrast medium enters the tissue surrounding the vein.
0037Although the situation illustrated in <figref idref="f0003">Fig 5</figref> is most likely to occur when the infusion commences, the processor unit constantly monitors the output from the probe 2 throughout the infusion procedure and can stop the pump at any time.
0038<figref idref="f0001">Figure 2</figref> shows a modified version of the embodiment of <figref idref="f0001">Figure 1</figref> in which an array of individual transducer elements is provided and in use is arranged on the patient's arm substantially transverse to the direction of flow of the vein (i.e. normal to the plane of <figref idref="f0001">Figure 1</figref>). Thus, the precise location of the vein need not be known prior to measurement. The signal from each transducer varies depending upon whether it is situated above tissue or above a vein (a Doppler shift will be detected if the transducer is directed towards moving fluid such as blood flowing in a vein). By monitoring the signals received by each transducer element in the array, the location of the vein can be detected. Once it has been determined which transducer elements are situated over the vein, those transducer elements can be monitored for changes in the flow velocity within the vein and hence it can be determined whether or not extravasation has occurred.
0039<figref idref="f0002">Figure 3</figref> shows an alternative embodiment of the invention in which the Doppler probe 2 consists of a number of individual transducer elements 2a-2f. These transducer elements are spaced at regular intervals to form an array which can be placed on a patient's arm downstream of cannula arrangement 13 to extend along the vein in the flow direction.
0040In a modified version of the embodiment of <figref idref="f0002">Figure 3</figref> (not illustrated), a two dimensional array of individual transducer elements is provided such that the elements extend both substantially transverse and substantially parallel to the direction of flow of the vein. In this way, the precise location of the vein need not be known at each measurement point before commencing measurement.
0041Instead, as previously described, it is determined which elements of the array are situated over the vein and those elements are monitored for changes in the flow velocity within the vein. Each such transducer element measures the flow rate at a respective point in the vein and this information is provided to the processor unit 4. The processor can therefore determine the approximate position along the vein at which extravasation has occurred. Thus for example, if the flow velocity measured at elements 2a to 2c corresponds to the flow velocity of the contrast medium within the vein but the velocity measured at element 2d does not, the processor determines that extravasation has occurred in the region of transducer element 2d. The remaining parts shown in <figref idref="f0002">Figure 3</figref> correspond to those shown in <figref idref="f0001">Figure 1</figref> and so are not described again here.
3 sheets
Sheet 1 Sheet 2 Sheet 3
Every citation, both ways
| Document | Relation | Office |
|---|---|---|
| WO9915074A | Cites | World Intellectual Property Organization (WIPO) |
| US5233994A | Cites | United States of America |
| US2002016547A1 | Cites | United States of America |
| US2002173725A1 | Cites | United States of America |
| US6425878B1 | Cites | United States of America |
19 members in 10 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 0228770 | United Kingdom | – | |
| 0228770 | United Kingdom | A | |
| 0305269 | United Kingdom | W |
Members19
| Document | Office | Kind | |
|---|---|---|---|
| GB0228770D0 | United Kingdom | D0 | |
| GB2396221A | United Kingdom | A | |
| CA2509332A1 | Canada | A1 | |
| WO2004052431A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2003288417A1 | Australia | A1 | |
| US2004176690A1 | United States of America | A1 | |
| EP1569707A1 | European Patent Office (EPO) | A1 | |
| JP2006508756A | Japan | A | |
| GB2396221B | United Kingdom | B | |
| US2008132797A1 | United States of America | A1 | |
| AU2003288417B2 | Australia | B2 | |
| EP1569707B1This record | European Patent Office (EPO) | B1 | |
| AT423585T | Austria | T | |
| ATE423585T1 | Austria | T1 | |
| DE60326379D1 | Germany | D1 | |
| ES2319411T3 | Spain | T3 | |
| JP4405398B2 | Japan | B2 | |
| US7801583B2 | United States of America | B2 | |
| CA2509332C | Canada | C |
58 legal events, as 8 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notification of lapseLapsedST | ST | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119 | R119 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed because of non-payment of the annual feeLapsedV1 | V1 | NL | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| No opposition filedOpposition26N | 26N | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Title (correction)EXTRAVASATION DETECTORRTI1 | RTI1 | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Request for extension of the european patent (deleted)DAX | DAX | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1569707
- Application
- 37803368
Titles3
- German
- Vorrichtung zur Erkennung von Extravasation
- English
- Extravasation detector
- French
- Détecteur d'extravasation
Classification
- CPC, 6
- A61M5/16836
- A61M5/168
- A61B8/06
- A61M5/16831
- A61B8/4236
- G01F1/663
- IPC, 2
- A61M5 168
- A61B8 06
Designated states27
- Contracting states, 27
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Hungary
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Romania
- Sweden
and 3 moreShow fewer
- Slovenia
- Slovakia
- Türkiye